Nadine T. Breslin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nadine T. Breslin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chandni Patel
Department of Pharmacy NewYork‐Presbyterian Hospital New York New York USA
1 shared publication- David M. Salerno
Department of Pharmacy NewYork‐Presbyterian Hospital New York New York USA
1 shared publication - Jessica Hedvat
NewYork‐Presbyterian Hospital Department of Pharmacy New York New York USA
1 shared publication Nicholas Jandovitz
Department of Pharmacy North Shore University Hospital Manhasset New York USA
1 shared publication- Nicholas W. Lange
NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
1 shared publication Sara Lee
Department of Pharmacy NewYork‐Presbyterian Hospital New York New York USA
1 shared publication
Latest Publications
- 10 November 2021
- Published by Wiley in Clinical Transplantation
- Vol. 36 (2) , e14529
Comparing weight‐based dosing of tacrolimus XR in obese and non‐obese renal transplant recipients
The recommended initial weight‐based dose of extended‐release (XR) tacrolimus (Envarsus XR) in kidney transplant recipients (KTR) is 0.14 mg/kg/day. However, no data exist regarding dosing recommendations for obese patients specifically. The aim of this study was to evaluate weight‐based dosing requirements in a cohort of obese KTR who were initiated on de novo tacrolimus XR post‐transplantation. The primary outcome was weight‐based dosing requirements (mg/kg/day) on post‐operative day (POD) 7 and 14. Of the 254 KTR, 81 (31%) were obese. The median therapeutic dose on POD7 was 0.1 versus 0.12 vs. 0.14 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p = .0001). This result was similar on POD14; median therapeutic dose was 0.09 versus 0.11 versus 0.15 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p < .001). Therapeutic dose on POD7 and POD14 based on ideal body was similar in all cohorts (p = .238, p = .923, respectively). This finding was supported by a strong linear relationship between ideal body weight (IBW) and therapeutic dose (r = .929). In both obese and non‐obese KTR, IBW had a stronger correlation with the therapeutic dose for tacrolimus XR.
- 10 November 2021
- Published by Wiley in Clinical Transplantation
- Vol. 36 (2) , e14529
Comparing weight‐based dosing of tacrolimus XR in obese and non‐obese renal transplant recipients
The recommended initial weight‐based dose of extended‐release (XR) tacrolimus (Envarsus XR) in kidney transplant recipients (KTR) is 0.14 mg/kg/day. However, no data exist regarding dosing recommendations for obese patients specifically. The aim of this study was to evaluate weight‐based dosing requirements in a cohort of obese KTR who were initiated on de novo tacrolimus XR post‐transplantation. The primary outcome was weight‐based dosing requirements (mg/kg/day) on post‐operative day (POD) 7 and 14. Of the 254 KTR, 81 (31%) were obese. The median therapeutic dose on POD7 was 0.1 versus 0.12 vs. 0.14 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p = .0001). This result was similar on POD14; median therapeutic dose was 0.09 versus 0.11 versus 0.15 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p < .001). Therapeutic dose on POD7 and POD14 based on ideal body was similar in all cohorts (p = .238, p = .923, respectively). This finding was supported by a strong linear relationship between ideal body weight (IBW) and therapeutic dose (r = .929). In both obese and non‐obese KTR, IBW had a stronger correlation with the therapeutic dose for tacrolimus XR.